WRAP-IT Study Version 1.0 29 July 2014

  • Research type

    Research Study

  • Full title

    World-wide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT)

  • IRAS ID

    170151

  • Contact name

    Katrien Vandersteegen

  • Contact email

    katrien.vandersteegen@medtronic.com

  • Sponsor organisation

    Medtronic Inc

  • Clinicaltrials.gov Identifier

    NCT02277990

  • Duration of Study in the UK

    3 years, 6 months, 0 days

  • Research summary

    The aim of this study is to evaluate the TYRX envelope a in subjects undergoing Cardiac Implantable Electronic Device (CIED, such as a pacemaker, a defibrillator or a cardiac resynchronization therapy device (CRT)) generator replacement, upgrade or revision or subjects that require a new (de novo) cardiac resynchronization therapy defibrillator (CRT-D). Subjects will be randomised to either have their CIED implanted inside the Medtronic TYRX envelope, an absorbable antibacterial pouch, or have their CIED implanted without the TYRX envelope. The purpose of the study is three-fold: firstly to fulfil post-approval requirements to facilitate collection of complications related to CIED procedure or system in subjects receiving the TYRX envelope. . Secondly, to evaluate the ability of the TYRX envelope to reduce major CIED infections within the first 12 months following CIED procedure. Thirdly, to prospectively characterize the performance of Medtronic's lead monitoring features in subjects whose CIED system includes a transvenous RV defibrillation lead. This is a world-wide study involving up to 225 sites with up to 7,764 subjects enrolled in order to randomise approximately 6,988 subjects. Randomisation will be 1:1 and be stratified by study site and device type, high power versus low power devices. Subjects receiving a low power device will be capped at approximately 25% of the total study population as relative to high power device recipients, subjects receiving a low power device may be at reduced risk of a major CIED infection. Thus, to ensure an adequate CIED infection event rate in the control arm, there is a desire to include a higher proportion of high power devices in the trial.

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    15/NW/0229

  • Date of REC Opinion

    12 May 2015

  • REC opinion

    Further Information Favourable Opinion